A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase II, randomised, double-blind, placebo-controlled study. Subjects with
histologically-confirmed oestrogen receptor negative (ER-), progesterone receptor negative
(PgR-) primary breast cancer breast cancer will be randomly assigned in a 2:1 ratio to
receive ZD1839 250 mg once daily or matching placebo for a total period of 5 weeks. Surgical
intervention will take place after 4 weeks (on Day 29) and treatment will continue for 1 week
after surgery.